KaliVir Immunotherapeutics宣布与罗氏达成临床试验合作与供应协议，共同评估VET3-TGI联合阿特珠单抗（Tecentriq®）治疗晚期实体瘤的效果——雅虎财经报道

KaliVir Immunotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate VET3-TGI in Combination with Atezolizumab (Tecentriq®) in Advanced Solid Tumors  Yahoo Finance